Vitamin B1 (benfotiamine) may slow the progression of Alzheimer’s.
Quoted:
“This 18-month, Phase 2 clinical trial will evaluate whether benfotiamine, an oral, easily absorbed [fat soluble] form of thiamine, can improve cognitive function and help preserve or potentially improvement participants ability to carry out daily routine activities.”
“Kobylarz, a geriatrician at Rutgers Health and the RWJBarnabas Health Medical Group, said the brain needs glucose for energy, “but in people with Alzheimer’s disease, brain cells often struggle to process that fuel. Benfotiamine works by significantly raising the levels of thiamine in the blood – up to 100 times higher than normal. It also reduces harmful changes to proteins and other molecules that depend on thiamine, including inflammation, buildup of harmful compounds that stick to proteins and form plaques and tangles that lead to nerve cell damage.”
By increasing thiamine levels, the treatment aims to help cells process glucose more efficiently, reduce inflammation and stop the buildup of harmful proteins that damage nerve cells.”
“This trial builds upon research from a 12-month, single-site pilot trial in people with early Alzheimer’s disease demonstrated benfotiamine was safe and well tolerated, with encouraging results in how the body processed and responded to the treatment. The study, published in the Journal of Alzheimer’s Disease in 2020, suggested a slowed rate of cognitive decline in 35 participants with cases of mild cognitive impairment or early Alzheimer's disease who took 300 mg benfotiamine pills twice daily.”


